INS and ovarian carcinoma: The summary random effect estimates ranged from 0.18 (95% confidence interval 0.12 to 0.25) for an association between metformin use and ovarian cancer occurrence up to 92.22 (− 73.15 to 257.59) for an association between insulin analogue use and birth weight.